These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 27321342

  • 1. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
    Abe M, Higuchi T, Moriuchi M, Okamura M, Tei R, Nagura C, Takashima H, Kikuchi F, Tomita H, Okada K.
    Diabetes Res Clin Pract; 2016 Jun; 116():244-52. PubMed ID: 27321342
    [Abstract] [Full Text] [Related]

  • 2. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
    Rosenstock J, Sankoh S, List JF.
    Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
    [Abstract] [Full Text] [Related]

  • 3. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Neumiller JJ, Campbell RK.
    Am J Health Syst Pharm; 2010 Sep 15; 67(18):1515-25. PubMed ID: 20811029
    [Abstract] [Full Text] [Related]

  • 4. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
    Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R, CV181-039 Investigators.
    Diabetes Obes Metab; 2009 Jun 15; 11(6):611-22. PubMed ID: 19515181
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
    Karyekar C, Donovan M, Allen E, Fleming D, Ravichandran S, Chen R.
    Postgrad Med; 2011 Jul 15; 123(4):63-70. PubMed ID: 21680990
    [Abstract] [Full Text] [Related]

  • 6. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
    Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I, D1680C00007 Investigators.
    Diabetes Obes Metab; 2011 Jun 15; 13(6):523-32. PubMed ID: 21332627
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension.
    Kadowaki T, Muto S, Ouchi Y, Shimazaki R, Seino Y.
    Expert Opin Pharmacother; 2017 Dec 15; 18(18):1903-1919. PubMed ID: 28901796
    [Abstract] [Full Text] [Related]

  • 8. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, Montanaro M, Fisher SA.
    Diabetes Obes Metab; 2014 May 15; 16(5):443-50. PubMed ID: 24205943
    [Abstract] [Full Text] [Related]

  • 9. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N.
    Diabetes Care; 2015 Nov 15; 38(11):2009-17. PubMed ID: 26246458
    [Abstract] [Full Text] [Related]

  • 10. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
    Rosenstock J, Mathieu C, Chen H, Garcia-Sanchez R, Saraiva GL.
    Arch Endocrinol Metab; 2018 Aug 15; 62(4):424-430. PubMed ID: 30304106
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.
    Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J.
    Diabetes Metab Res Rev; 2012 Mar 15; 28(3):268-75. PubMed ID: 22081481
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I.
    Diabetes Metab Res Rev; 2010 Oct 15; 26(7):540-9. PubMed ID: 20824678
    [Abstract] [Full Text] [Related]

  • 13. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study.
    Leibowitz G, Cahn A, Bhatt DL, Hirshberg B, Mosenzon O, Wei C, Jermendy G, Sheu WH, Sendon JL, Im K, Braunwald E, Scirica BM, Raz I.
    Diabetes Obes Metab; 2015 May 15; 17(5):487-94. PubMed ID: 25656169
    [Abstract] [Full Text] [Related]

  • 14. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
    Fujii Y, Abe M, Higuchi T, Mizuno M, Suzuki H, Matsumoto S, Ito M, Maruyama N, Okada K, Soma M.
    Expert Opin Pharmacother; 2013 Feb 15; 14(3):259-67. PubMed ID: 23289982
    [Abstract] [Full Text] [Related]

  • 15. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
    Bonora E, Bryzinski B, Hirshberg B, Cook W.
    Nutr Metab Cardiovasc Dis; 2016 May 15; 26(5):374-9. PubMed ID: 27033025
    [Abstract] [Full Text] [Related]

  • 16. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
    Cook W, Minervini G, Bryzinski B, Hirshberg B.
    Postgrad Med; 2014 Oct 15; 126(6):19-32. PubMed ID: 25414932
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
    Hollander PL, Li J, Frederich R, Allen E, Chen R, CV181013 Investigators.
    Diab Vasc Dis Res; 2011 Apr 15; 8(2):125-35. PubMed ID: 21562064
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.